X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (89) 89
oncology (81) 81
female (78) 78
middle aged (75) 75
aged (70) 70
adult (65) 65
chemotherapy (55) 55
index medicus (46) 46
cancer (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
male (34) 34
breast cancer (32) 32
treatment outcome (31) 31
paclitaxel (30) 30
aged, 80 and over (29) 29
prognosis (28) 28
breast neoplasms - drug therapy (26) 26
human (21) 21
research (21) 21
article (20) 20
epirubicin (20) 20
therapy (20) 20
trial (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
carcinoma (19) 19
disease-free survival (19) 19
ovarian cancer (18) 18
priority journal (18) 18
antineoplastic combined chemotherapy protocols (17) 17
carboplatin (17) 17
colorectal cancer (17) 17
paclitaxel - administration & dosage (17) 17
cisplatin (16) 16
medicine (16) 16
neoplasm staging (16) 16
survival (16) 16
survival analysis (16) 16
survival rate (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (15) 15
chemotherapy, adjuvant (15) 15
cyclophosphamide (15) 15
major clinical study (15) 15
breast neoplasms - pathology (14) 14
controlled study (14) 14
genetic aspects (14) 14
mutation (14) 14
young adult (14) 14
clinical trials (13) 13
fluorouracil (13) 13
oncology, experimental (13) 13
tumors (13) 13
breast neoplasms - genetics (12) 12
drug administration schedule (12) 12
ovarian neoplasms - drug therapy (12) 12
oxaliplatin (12) 12
research article (12) 12
retrospective studies (12) 12
anemia (11) 11
antineoplastic agents (11) 11
breast neoplasms - mortality (11) 11
cancer survival (11) 11
cancer therapies (11) 11
clinical trial (11) 11
health aspects (11) 11
immunohistochemistry (11) 11
patients (11) 11
protein expression (11) 11
analysis (10) 10
carboplatin - administration & dosage (10) 10
dose-response relationship, drug (10) 10
doxorubicin (10) 10
fluorouracil - administration & dosage (10) 10
gemcitabine (10) 10
greece (10) 10
medical prognosis (10) 10
medicine & public health (10) 10
metastasis (10) 10
neutropenia (10) 10
antineoplastic agents - therapeutic use (9) 9
care and treatment (9) 9
drug therapy (9) 9
hematology, oncology and palliative medicine (9) 9
hospitals (9) 9
medical research (9) 9
ovarian neoplasms - pathology (9) 9
prospective studies (9) 9
advanced cancer (8) 8
alopecia (8) 8
breast neoplasms (8) 8
cancer chemotherapy (8) 8
cancer patients (8) 8
cancer research (8) 8
colorectal neoplasms - drug therapy (8) 8
combination (8) 8
cyclophosphamide - administration & dosage (8) 8
dense sequential chemotherapy (8) 8
diarrhea (8) 8
drug efficacy (8) 8
expression (8) 8
kaplan-meier estimate (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, p. e0123902
Journal Article
by Phelan, Catherine M and Kuchenbaecker, Karoline B and Tyrer, Jonathan P and Kar, Siddhartha P and Lawrenson, Kate and Winham, Stacey J and Dennis, Joe and Pirie, Ailith and Riggan, Marjorie J and Chornokur, Ganna and Earp, Madalene A and Lyra, Paulo C and Lee, Janet M and Coetzee, Simon and Beesley, Jonathan and McGuffog, Lesley and Soucy, Penny and Dicks, Ed and Lee, Anew and Barrowdale, Daniel and Lecarpentier, Julie and Leslie, Goska and Aalfs, Cora M and Aben, Katja K. H and Adams, Marcia and Adlard, Julian and Anulis, Irene L and Anton-Culver, Hoda and Antonenkova, Natalia and Aravantinos, Gerasimos and Arnold, Norbert and Arun, Banu K and Arver, Brita and Azzollini, Jacopo and Balmaña, Judith and Banerjee, Susana N and Barjhoux, Laure and Barkardottir, Rosa B and Bean, Yukie and Beckmann, Matthias W and Beeghly-Fadiel, Alicia and Benitez, Javier and Bermisheva, Marina and Bernardini, Marcus Q and Birrer, Michael J and Bjorge, Line and Black, Amanda and Blankstein, Kenneth and Blok, Marinus J and Bodelon, Clara and Bogdanova, Natalia and Bojesen, Anders and Bonanni, Bernardo and Borg, Åke and Bradbury, Angela R and Brenton, James D and Brewer, Carole and Brinton, Louise and Broberg, Per and Brooks-Wilson, Angela and Bruinsma, Fiona and Brunet, Joan and Buecher, Bruno and Butzow, Ralf and Buys, Sauna S and Caldes, Trinidad and Caligo, Maria A and Campbell, Ian and Cannioto, Rikki and Carney, Michael E and Cescon, Terence and Chan, Salina B and Chang-Claude, Jenny and Chanock, Stephen and Chen, Xiao Qing and Chiew, Yoke-Eng and Chiquette, Jocelyne and Chung, Wendy K and Claes, Kathleen B. M and Conner, Thomas and Cook, Linda S and Cook, Jackie and Cramer, Daniel W and Cunningham, Julie M and D'Aloisio, Aimee A and Daly, Mary B and Damiola, Francesca and Damirovna, Sakaeva Dina and Dansonka-Mieszkowska, Agnieszka and Dao, Fanny and Davidson, Rosemarie and Defazio, Anna and Delnatte, Capucine and Doheny, Kimberly F and Diez, Orland and Ding, Yuan Chun and Doherty, Jennifer Anne and Domchek, Susan M and Dorfling, Cecilia M and Dörk, Thilo and ... and KConFab Investigators and EMEMBRACE Study and GEMO Study Collaborators and OPAL Study Grp and AOCS Study Grp and HEBON Study and AOCS study group and EMBRACE Study and OPAL study group and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Ortopedi and Uppsala universitet and Institutionen för kirurgiska vetenskaper
Nature genetics, ISSN 1061-4036, 2017, Volume 49, Issue 5, pp. 680 - 691
Journal Article
BMC Cancer, ISSN 1471-2407, 05/2013, Volume 13, Issue 1, pp. 263 - 263
Background: Metronomic chemotherapy is considered an anti-angiogenic therapy that involves chronic administration of low-dose chemotherapy at regular short... 
Metronomic-chemotherapy | Antiangiogenic | Vinorelbine | Cancer | ANGIOGENESIS | CYCLOPHOSPHAMIDE | GROUP HECOG | RECEPTOR | TOXICITY | CHEMOTHERAPY | THERAPY | ONCOLOGY | RESISTANCE | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Liver Neoplasms - mortality | Dose-Response Relationship, Drug | Young Adult | Antineoplastic Agents, Phytogenic - administration & dosage | Vinblastine - analogs & derivatives | Biomarkers, Tumor - metabolism | Adult | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Real-Time Polymerase Chain Reaction | Prostatic Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Prostatic Neoplasms - pathology | Enzyme-Linked Immunosorbent Assay | Time-to-Treatment | Administration, Oral | RNA, Messenger - genetics | Translational Medical Research | Liver Neoplasms - drug therapy | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Prostatic Neoplasms - mortality | Breast Neoplasms - pathology | Adolescent | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Drug therapy | Metastasis | Research | Care and treatment | Cancer patients | Chemotherapy | Oncology, Experimental | Fibroblast growth factors | Lung cancer, Non-small cell
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 01/2012, Volume 10, Issue 1, pp. 10 - 10
Background: HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with... 
Mrna expression | Anthracyclines | Gene amplification | Top2a | Randomized study | Cish | Early breast cancer | Taxanes | Her2 | TOP2A | early breast cancer | PREDICTIVE MARKERS | MEDICINE, RESEARCH & EXPERIMENTAL | CISH | TOPOISOMERASE-II-ALPHA | taxanes | IN-SITU HYBRIDIZATION | QUANTITATIVE PCR | ESTROGEN-RECEPTOR | mRNA expression | PARAFFIN-EMBEDDED TISSUE | MESSENGER-RNA | PROTEIN EXPRESSION | CELL-CYCLE | anthracyclines | HER2 | gene amplification | randomized study | Multivariate Analysis | Receptors, Estrogen - metabolism | Antibiotics, Antineoplastic - pharmacology | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Ki-67 Antigen - metabolism | Gene Expression Profiling | RNA, Messenger - metabolism | Receptors, Progesterone - metabolism | DNA-Binding Proteins - metabolism | Dose-Response Relationship, Drug | Paraffin Embedding | Young Adult | Poly-ADP-Ribose Binding Proteins | Breast Neoplasms - enzymology | Antigens, Neoplasm - metabolism | Adult | Female | Chemotherapy, Adjuvant | Gene Expression Regulation, Neoplastic - drug effects | Tissue Fixation | Genes, Neoplasm - genetics | Antigens, Neoplasm - genetics | DNA Topoisomerases, Type II - metabolism | RNA, Messenger - genetics | Risk Factors | Proportional Hazards Models | Treatment Outcome | DNA-Binding Proteins - genetics | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Antibiotics, Antineoplastic - therapeutic use | Breast Neoplasms - pathology | Epirubicin - therapeutic use | DNA Topoisomerases, Type II - genetics | Aged | Epirubicin - pharmacology | Genes | Physiological aspects | Breast cancer | Genetic aspects | Research | Epirubicin | Drug therapy | Health aspects | DNA topoisomerase II | Medical research | Oncology | Cytotoxicity | Cancer therapies | Manuscripts | Medicine | Pathology | Chemotherapy | Hospitals | Writing | Drug dosages | Tumors
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2015, Volume 10, Issue 10, p. e0140293
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2769 - 2769
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, p. e0180489
Background-Aim To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various... 
OVEREXPRESSION | COOPERATIVE ONCOLOGY GROUP | PROGNOSTIC-FACTOR | EPIRUBICIN | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | DENSE SEQUENTIAL CHEMOTHERAPY | INHIBITORS | P21 | P27(KIP1) | Immunohistochemistry | Prognosis | Cyclin-Dependent Kinase Inhibitor p27 - analysis | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Young Adult | Cyclin D1 - analysis | Tumor Suppressor Protein p53 - analysis | Cyclin-Dependent Kinase Inhibitor p21 - analysis | Breast - drug effects | Breast Neoplasms - pathology | Triple Negative Breast Neoplasms - diagnosis | Cyclin E - analysis | Survival Analysis | Triple Negative Breast Neoplasms - pathology | Adult | Female | Aged | Breast Neoplasms - diagnosis | Oncogene Proteins - analysis | Breast - pathology | Usage | Analysis | Cell cycle | Clinical trials | Breast cancer | Research | Health sciences | GTP-binding protein | Regulators | Laboratories | Molecular clusters | p53 Protein | Oncology | Paraffin | Cyclin D1 | Kinases | Tissues | Cancer therapies | Formaldehyde | Cell adhesion & migration | Proteins | Medical research | Cyclin-dependent kinases | Clustering | Medicine | Pathology | Cyclin-dependent kinase inhibitor p21 | Hospitals | Medical prognosis | Breast | Tumors | Cancer | Apoptosis
Journal Article
BMC Medicine, ISSN 1741-7015, 01/2011, Volume 9, Issue 1, pp. 10 - 10
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to... 
1ST-LINE TREATMENT | PLUS LEUCOVORIN | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | PERSPECTIVES | CAMPTOTHECINS | OXALIPLATIN | METASTATIC COLORECTAL-CANCER | FOLFIRI | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Greece | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Chemotherapy | Usage | Colon cancer | Patient outcomes | Leucovorin | Drug therapy, Combination | Drug therapy | Health aspects | Fluorouracil | Cancer | Medical imaging | Heart attacks | Statistical analysis | Mortality | Colorectal cancer | Clinical trials | Histology | Cancer therapies | Manuscripts | Medicine | Hospitals | Tomography | Clinical medicine | Acquisitions & mergers | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, p. e0124612
Background Although host immune response is an emerging prognostic factor for colorectal cancer, there is no consensus on the optimal methodology, surrogate... 
COLON-CANCER | LOCALIZATION | CELLS | METHYLATION | MULTIDISCIPLINARY SCIENCES | ESTROGEN | EPIDEMIOLOGY | Antigens, CD - immunology | Chemokines, CXC - immunology | Prognosis | Prospective Studies | Age Factors | Tissue Array Analysis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Neoplasm Proteins - immunology | Male | Gene Expression Profiling | Estrogen Receptor alpha - immunology | Antigens, CD - genetics | Colorectal Neoplasms - diagnosis | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Neoplasm Proteins - genetics | Transcription Factors - immunology | Colorectal Neoplasms - mortality | Adenocarcinoma - immunology | Lymphatic Metastasis | Transcription Factors - genetics | Chemokines, CXC - genetics | Immunity, Innate | Adenocarcinoma - diagnosis | Colorectal Neoplasms - immunology | Estrogen Receptor alpha - genetics | Survival Analysis | Heterozygote | Aged | Neoplasm Staging | Adenocarcinoma - mortality | Care and treatment | Chemotherapy | Analysis | Colorectal cancer | Genetic aspects | Gene expression | Cancer | Laboratories | CD8 antigen | Mucosa | Colorectal carcinoma | CXCL13 protein | Oncology | Necrosis | K-Ras protein | Metastases | ESR1 protein | Colon cancer | DNA methylation | Foxp3 protein | Colon | Localization | Immune system | Medical research | Immune response | Internal medicine | Invasiveness | Patients | CD4 antigen | Medicine | Cores | Pathology | Hospitals | DNA microarrays | Medical prognosis | Infiltration | Mutation | Snail protein | Tumors
Journal Article